TJPC(SH:600488) Zhi Tong Cai Jing·2025-10-31 08:10Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Pharmaceutical Peace Co., Ltd. (津药和平), has received the drug registration certificate for Butorphanol Tartrate Injection from the National Medical Products Administration (NMPA) [1] Group 1: Product Development - Butorphanol Tartrate Injection is classified as a second-class psychoactive drug under the national regulations and is indicated for the treatment of various cancer-related pain and postoperative pain [1] - The application for the drug's domestic production registration was submitted to the NMPA in October 2023 and was accepted [1] - The drug registration certificate was officially granted in October 2025, with a total research and development investment of approximately 22 million yuan (around 3.1 million USD) in the Butorphanol Tartrate Injection project to date [1]